Union Development Oy

Why Europe Should Be on Every Biotech’s Clinical Strategy Map ? Europe offers a powerful combination of regulatory credibility, patient access, and strategic value creation. With a population of nearly 600 million people (about 450 million within the EU), Europe provides access to large and diverse patient populations supported by advanced healthcare infrastructure. Centralized healthcare systems, national registries, and experienced site networks can significantly accelerate patient enrollment. Another major advantage: speed. Clinical trial approvals can take a maximum of 60 days, and in some countries as little as 30 days for mono-national trials — making Europe an excellent option for Phase I and early Phase I/II studies. Early engagement with the European Medicines Agency (EMA) as well as local Regulatory Authorities also provides valuable scientific advice that strengthens both European and global development strategies. And then there’s cost efficiency. Compared with U.S. sites, many European countries offer high-quality investigators, faster recruitment, and significantly lower costs. CRO and site expenses can be 20–50% lower than in the U.S., directly improving your development budget. Efficiency extends runway — and runway is strategy. But many biotech companies ask the same questions: - Where is the best-fit location for my trial? - Which sites and partners should I work with? - How do I ensure pricing is fair and competitive? - How can we coordinate operations in Europe without a local office? The good news: you don’t have to navigate it alone. That’s exactly where Union Development can help. 📩 Reach out to learn how we support biotech companies in designing and executing efficient clinical trials across Europe. #biotech #clinicaltrials #clinicaldevelopment #drugdevelopment

Why Europe Should Be on Every Biotech’s Clinical Strategy Map ? Europe offers a powerful combination of regulatory credibility, patient access, and strategic value creation. With a population of nearly 600 million people (about 450 million within the EU), Europe provides access to large and diverse patient populations supported by advanced healthcare infrastructure. Centralized healthcare systems, national registries, and experienced site networks can significantly accelerate patient enrollment. Another major advantage: speed. Clinical trial approvals can take a maximum of 60 days, and in some countries as little as 30 days for mono-national trials — making Europe an excellent option for Phase I and early Phase I/II studies. Early engagement with the European Medicines Agency (EMA) as well as local Regulatory Authorities also provides valuable scientific advice that strengthens both European and global development strategies. And then there’s cost efficiency. Compared with U.S. sites, many European countries offer high-quality investigators, faster recruitment, and significantly lower costs. CRO and site expenses can be 20–50% lower than in the U.S., directly improving your development budget. Efficiency extends runway — and runway is strategy. But many biotech companies ask the same questions: - Where is the best-fit location for my trial? - Which sites and partners should I work with? - How do I ensure pricing is fair and competitive? - How can we coordinate operations in Europe without a local office? The good news: you don’t have to navigate it alone. That’s exactly where Union Development can help. 📩 Reach out to learn how we support biotech companies in designing and executing efficient clinical trials across Europe. #biotech #clinicaltrials #clinicaldevelopment #drugdevelopment

We don’t just deliver reports — we deliver progress. Progress that accelerates your pipeline, strengthens operations, and gets studies moving — faster. Our DevOps model fills capability gaps, provides flexible resources, and accelerates execution by bringing the right expertise, at the right time, in the right place. No fancy reports — just measurable progress. We identify best-fit solutions for your clinical trials, where recruitment, speed, quality, and strategic value align. Through our global network, we connect you with high-performing CROs and specialized providers — including hidden gems that truly deliver. Our OMG governance model ensures your study budgets are accurate, controlled, and optimized from the start. 📩 Let’s connect and discuss how we can move your projects and pipeline forward. #ClinicalOperations #DevOps #ClinicalTrials #PipelineAcceleration #StrategicExecution #Biotech #Pharma

As 2025 comes to a close, it’s fair to say it was… an interesting year. In a good way. We had the privilege of meeting and collaborating with outstanding professionals around the world, building new partnerships, closing transactions, and launching projects for biotech, pharma, and medical device companies originating from three continents and operating across four continents. A practical reminder that our belief holds true: you don’t need to be a global company to have a global advantage. In 2026, we’ll continue our mission to empower Biotech, Pharma, and Medical Device companies through our global BESTFIT Solutions, DEVOPS Management (Development Operations), and OMG Outsourcing Managementservices—helping organizations leverage global capabilities to drive R&D success. For now, we’re taking a short break before doing it all again. Wishing you all a Merry Christmas, Happy Holidays, and a successful and healthy 2026.

Introducing Union Development’s dynamic duo, part 2 - Mark Wood A multi-talented multitasker, value driven biopharma R&D professional with a strong data-science background through various CRO roles to lead biotech’s R&D programs you know - this is Mark. He has been in the CRO and clinical operations business since 2003 and seen a lot from almost every angle of biopharma R&D and this intelligence and knowledge translates to what he can share through our DEVOPS services. His eagerness, intelligence and innovative way of working seem to be attributes that his customers, co-workers and colleagues’ value a lot. Two strapping sons keep him not only busy but also alert. A master chef, especially when it comes to BBQs and Italian dishes, and a true epicure. Also, quite a handyman while spending his time at his summer mansion. Need help with your programs, now you know who to contact.

Introducing Union Development’s dynamic duo, part 1 - Hannu Rautanen It has been said that Hannu is a visionary business development leader who is always looking at the best possible solution for his customers. Actually, this is precisely what is behind our core service, BESTFIT Solutions - so perhaps a true and valid point. He has been in the CRO and clinical operations business since 2003 and seen various companies in various positions including business development and outsourcing management and in numerous sectors such as late phase, early phase, site management, bioanalytical, CDMO and so on and so forth. Behind his never-ending motivation and dynamic attitude are his 2 beautiful daughters and a handsome son, as well as a granddaughter (cutie herself) who ensure that no savings are left behind. In his free time, if there is any, he is a wannabe golfer, ex-free skier (with too many knee injuries), outdoorsman and most of all a handyman - always having a project or two to fix. Wherever you are planning your next trial he is the man to start planning your study constellation with.

🚨 RISK-SHARING & CO-FINANCING by CROs 💰 Smart strategy or strategic smokescreen? More CROs are offering risk-sharing and co-financing models to biotech. Even those that don’t advertise it. ✅ Sounds great: They’re invested in your success. They help ease funding pressure. Performance should improve... right? But ask yourself: 🔍 Are the countries selected truly optimal for recruitment? 🎯 Is the study designed for your strategy—or theirs? 💸 Are the true costs and risks visible beneath the pitch deck? At Union Development, we bring clarity to complexity. Our BESTFIT model + OMG (Outsourcing Management) = an independent, objective review of: 📊 CRO performance potential 🌍 Study design & country mix 📑 Real-world budget validation 💡 Don’t just accept the deal—interrogate it. 👉 Let’s ensure your risk-sharing model works for you. #Biotech #ClinicalTrials #CRO #RiskSharing #CoFinancing #ClinicalDevelopment #Strategy #UnionDevelopment #BESTFIT #OutsourcingManagement